Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Enrolling by invitation × INDUSTRY × Afatinib × Clear all

Phase

Status

Completed 59 Terminated 4 Approved for marketing 3 Unknown 2 Active not recruiting 2 No longer available 1 Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

zilucoplan 1 zanidatamab 1 tislelizumab 1 somapacitan 1 sitravatinib 1 rozanolixizumab 1 pamiparib 1 lenvatinib 1 ibrutinib 1 futibatinib 1 exemestane 1 enzalutamide 1 durvalumab 1 decitabine and cedazuridine drug combination 1 cemiplimab 1 brexucabtagene autoleucel 1 axicabtagene ciloleucel 1 Temozolomide 1 Tamoxifen 1 Robotic Surgical Procedures 1 Observation 1 Letrozole 1 Lenalidomide 1 JNJ-64619178 1 JNJ-64264681 1 Irinotecan 1 Inosine Monophosphate 1 HMPL-013 1 Fulvestrant 1 Folfox protocol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06759857 2025-01-06

FHND9041

Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.

Phase 3 Enrolling by invitation

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡